MAR — Marriott International, Inc.

As of 2026-09-13 the market has cooled from bullish to indifferent. The analyst panel is split (23 buy / 28 hold / 1 sell, consensus rating "Hold") with an average price target near $386.71, about 15% above the $334.69 spot price, so nobody is calling it broken. But price action tells the real story: -5.61% over one month and -16.86% over three months despite a Q2 2026 beat (adjusted EPS $3.19 vs ~$3.08 consensus) and a guidance raise (global RevPAR +3-3.5%, adjusted EBITDA $5.97-6.03B, adjusted EPS growth 16-18%). That combination - estimates up, price down - means the stock is being de-rated on multiple and on macro/travel-sector rotation, not on deteriorating fundamentals. Institutions own over 70% of the float and are trimming around the edges rather than exiting.

Revenue has compounded from $5.93B in Q3 2023 to $7.07B in Q2 2026, and the last four YoY prints are remarkably steady: +3.7% (Q3 2025), +4.1% (Q4 2025), +6.2% (Q1 2026), +4.9% (Q2 2026). That is stable mid-single-digit growth - not accelerating, not decelerating - and it is the profile you expect from an asset-light fee model riding ~5-6% net room growth plus ~3-4% RevPAR. Operating margin is basically flat: 17.4% in Q2 2026 vs 18.3% in Q2 2025, with Q4 the seasonal trough (11.6% in Q4 2025 vs 11.7% in Q4 2024). GAAP diluted EPS of $2.84 grew only ~2% YoY versus ~12% for adjusted EPS ($3.19) - the wedge is interest expense on a heavier debt load, not operations. Free cash flow is positive in 11 of the last 12 quarters (TTM $3.13B) and the accruals ratio of -0.65% as of 2026-06-30 means cash generation is running ahead of reported net income, a genuine quality positive. The one unambiguously structural (not blip) trend is the balance sheet: long-term debt up from $11.32B in Dec 2023 to $16.46B in Jun 2026 while stockholders' equity fell from -$0.68B to -$4.53B, i.e. an increasing share of the buyback is debt-funded.

Fair, and no longer expensive, as of 2026-09-13. On the data: 34.9x TTM P/E against a 5-year average of 31.5x, P/S 3.24 against 3.09, PEG a startling 4.3, and the deterministic screener's EV/EBITDA of 22.8 and P/C of 195. On trailing numbers MAR still screens ~10% rich versus its own five-year history, which is why the score labels valuation "Neutral vs. its own history." But forward is what matters: $334.69 against consensus next-FY EPS of $11.716 is 28.6x, versus roughly 34x when the stock hit $410.98 in June 2026. So the 3-month drawdown is almost entirely multiple compression, and 28.6x for a business guiding 16-18% adjusted EPS growth in 2026 with a record 629,000-room pipeline is defensible - not cheap, but not a bubble either. My own fair value (~$350) sits ~10% below the $386.71 analyst consensus, so I would not chase the sell-side target.

The key read as of 2026-09-13: price has fallen ~19% from the June 2026 high while forward EPS estimates went UP - management raised full-year 2026 adjusted EPS growth guidance to 16-18% and lifted EBITDA guidance to $5.97-6.03B on August 3, 2026. That is a de-rating, not an earnings miss. At $334.69 the market is paying ~28.6x forward adjusted EPS and implicitly assuming roughly 10-12% long-run EPS growth; that is a reasonable assumption but leaves no cushion. Watch the Q3 2026 print (late Oct/early Nov 2026): guided RevPAR of +3.5-4% and EPS of $2.74-2.82. If that lands and the co-brand credit-card renewals add the expected ~$30M of H2 fees, the gap between price and earnings should close. If RevPAR slips toward +2% or the card renewals slip, 28.6x is the wrong multiple and the stock has more downside - the estimate revision direction is the swing factor, not the current quarter's beat.

Weak, but not yet washed out. As of 2026-09-13, RSI(14) was 38.04 - below neutral, above the 30 oversold line - while price sat 3.43% below its 20-day SMA, 6.66% below its 50-day and 3.17% below its 200-day. Losing the 200-day while returning -16.86% over three months is a genuine downtrend, not chop, and the stock sits in the lower-middle of its 52-week range ($256.76-$410.98). There is no oversold capitulation signal and no trend-reversal signal either. Timing implication: this is a "wait for confirmation" setup - either a reclaim of the 50-day (which would imply roughly a 7% move up from $334.69) or an RSI dip under 30 with a reversal candle - rather than a buy-the-dip level on the data as of that date.

• Interest rates: higher-for-longer rates cut both ways for MAR - they throttle new hotel construction and developer financing (supply-friendly for incumbents) but raise MAR's own refinancing cost on $16.46B of long-term debt as of 2026-06-30 and make debt-funded buybacks less attractive.
• US consumer spending normalization: management says travel demand is holding across income tiers and US/Canada RevPAR rose 5.0% in Q2 2026, but any softening in discretionary travel hits fee revenue and the multiple simultaneously.
• Geopolitics and regional conflict: International RevPAR fell 0.5% in Q2 2026 while US/Canada rose 5.0%, directly attributed to Middle East friction - a persistent drag on the fastest-growing part of the system.
• Sector rotation away from consumer-cyclical travel names: a -16.86% three-month return alongside a +6.65% six-month return looks like de-rating/rotation rather than company-specific deterioration.
• Loyalty and co-branded credit economics: Chase/Amex card fees are growing faster than room revenue and are far less cyclical than RevPAR, a genuine structural buffer - but also a concentration risk if partner terms reset.

• Q3 2026 earnings, expected late October/early November 2026: guided global RevPAR growth of 3.5-4% and diluted EPS of $2.74-2.82 - a clean beat and reaffirmed full-year guide would likely break the three-month downtrend.
• Final execution of long-term co-branded credit card renewals, projected to add roughly $30M of incremental fee revenue in H2 2026 - high-margin, multiple-supportive revenue.
• Record development pipeline of nearly 4,200 properties / ~629,000 rooms converting into net-unit growth, the core long-run fee engine.
• Continued capital return: $1.1B of buybacks in Q2 2026 alone and roughly $2.6B returned year-to-date through July 2026, which mechanically supports EPS even if EBITDA is flat.
• The September 2026 cloud-based guest room entertainment/technology partnership - a cost-efficiency and guest-experience lever across the system.

• Valuation/multiple risk: at 28.6x forward adjusted EPS as of 2026-09-13, MAR needs mid-teens EPS growth to keep working; a PEG of 4.3 on trailing numbers shows how much optimism is embedded.
• Balance sheet deterioration: long-term debt up ~45% since Dec 2023 to $16.46B while stockholders' equity fell to -$4.53B as of 2026-06-30 - buybacks are increasingly debt-funded, and GAAP EPS grew only ~2% YoY in Q2 2026 versus ~12% adjusted because of the interest drag.
• RevPAR shock: a deceleration toward +2% or below would hit fee revenue and the 28.6x multiple at the same time, the classic double-whammy for asset-light lodging.
• International/geopolitical exposure: International RevPAR is already negative (-0.5% in Q2 2026) on Middle East conflict, and further escalation could widen that gap.
• Partner concentration in the loyalty/credit-card ecosystem: the pending Chase/Amex renewals are a catalyst if favorable and a real risk if terms are negotiated less generously than the ~$30M H2 2026 expectation.

Not a compelling buy at $334.69 as of 2026-09-13, though also not a broken business. Quality is genuinely high - 15.6% ROIC, ~$3.13B trailing free cash flow with cash earnings ahead of reported net income (accruals ratio -0.65%), a raised FY2026 guide, and a record 629,000-room pipeline. But the price still asks for ~28.6x forward adjusted EPS, the stock is below all three major moving averages with RSI at 38.0, and the balance sheet has become progressively more leveraged to fund buybacks. My independently calculated fair value of about $350 implies only ~5% upside, so I would want either a lower entry or evidence of RevPAR re-acceleration before committing new capital. This is analysis, not personalized financial advice.

I valued MAR on forward earnings: a next-twelve-month adjusted EPS of ~$12.71, built from FY2026E adjusted EPS of $11.716 (Q4 2026E ~$3.25 after $8.47 of 9-month adjusted EPS), plus ~11% growth into Q1-Q3 2027 ($2.83 / $3.54 / $3.09), times a 27.5x multiple - a deliberate discount to the 31.5x 5-year average trailing P/E of 31.53 given a ~4.5% risk-free rate, a Neutral own-history valuation reading, and rising leverage. Cross-check: ~16.5x FY2027E adjusted EBITDA of ~$6.6B less ~$16.5B of net debt on ~259M shares gives ~$357, so the two methods bracket the same ~$350 figure.